- Home
- BATL vs FBRX Comparison
BATL vs FBRX Comparison
Compare BATL & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- FBRX
- Stock Information
- Founded
- BATL 1987
- FBRX N/A
- Country
- BATL United States
- FBRX United States
- Employees
- BATL N/A
- FBRX N/A
- Industry
- BATL Oil & Gas Production
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- BATL Energy
- FBRX Health Care
- Exchange
- BATL Nasdaq
- FBRX Nasdaq
- Market Cap
- BATL 29.9M
- FBRX 35.3M
- IPO Year
- BATL N/A
- FBRX N/A
- Fundamental
- Price
- BATL $1.47
- FBRX $7.35
- Analyst Decision
- BATL
- FBRX Strong Buy
- Analyst Count
- BATL 0
- FBRX 4
- Target Price
- BATL N/A
- FBRX $76.58
- AVG Volume (30 Days)
- BATL 56.9K
- FBRX 54.6K
- Earning Date
- BATL 05-14-2025
- FBRX 05-12-2025
- Dividend Yield
- BATL N/A
- FBRX N/A
- EPS Growth
- BATL N/A
- FBRX N/A
- EPS
- BATL N/A
- FBRX N/A
- Revenue
- BATL $193,893,000.00
- FBRX N/A
- Revenue This Year
- BATL N/A
- FBRX N/A
- Revenue Next Year
- BATL N/A
- FBRX N/A
- P/E Ratio
- BATL N/A
- FBRX N/A
- Revenue Growth
- BATL N/A
- FBRX N/A
- 52 Week Low
- BATL $1.05
- FBRX $4.11
- 52 Week High
- BATL $7.08
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- BATL 56.10
- FBRX 44.84
- Support Level
- BATL $1.12
- FBRX $7.10
- Resistance Level
- BATL $1.34
- FBRX $9.04
- Average True Range (ATR)
- BATL 0.12
- FBRX 1.32
- MACD
- BATL 0.05
- FBRX 0.34
- Stochastic Oscillator
- BATL 93.02
- FBRX 50.62
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent oil and gas producer operating exclusively in the Delaware Basin. It is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the United States. The company operates in one segment which focuses on oil and natural gas acquisition, production, exploration, and development.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).